Glomerulonephritis

Prompt identification of ANCA and anti-GBM antibodies allows for early initiation of treatment and may improve patient outcomes. Antibodies to GBM antigens cause glomerulonephritis, Goodpasture’s syndrome, and, less commonly, pulmonary hemosiderosis. Anti-neutrophil cytoplasmic antibodies occur in various types of autoimmune diseases including renal limited vasculitis (e.g., Wegener’s granulomatosis [WG] or microscopic polyangiitis [MPA]) and pauci-immune necrotizing GN.¹ Comprehensive testing, prompt result reporting, and access to more than 150 years of advanced medical knowledge deliver the answers your practice needs to keep care local.

Key testing

• GBM | Glomerular Basement Membrane Antibodies, IgG, Serum

Advantages

• Identifies GBM antibodies to aid in diagnosing anti-GBM disease or Goodpasture’s syndrome.
• Evaluates patients with rapid-onset renal failure and evidence of possible anti-GBM disease.
• Evaluates patients with suspected nephritic syndrome and active urinary sediments to determine the clinical presentation.
• Evaluates patients with pulmonary hemorrhage.
• Guides treatment plan development.
• Monitors treatment effectiveness and progression of renal injury in patients with anti-GBM diseases.
• Confirms diagnosis in conjunction with the Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum (Mayo ID: VASC).

• VASC | Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum

Advantages

• Distinguishes Wegener’s granulomatosis from microscopic polyangiitis by identifying the presence of antineutrophil cytoplasmic antibodies.
• Confirms disease subtype when a patient presents with nephritic syndrome.
• Establishes if a patient with anti-GBM disease is also ANCA positive to predict outcomes.
• Guides treatment plan development.
• Confirms initial diagnosis in conjunction with Glomerular Basement Membrane Antibodies, IgG, Serum (Mayo ID: GBM).